化工社化工社 化学情報印刷レポート · 研究参考用
ラニチジン塩酸塩
ラニチジン塩酸塩 · ザンタック · ツルデック · セオトタック · ラデン · ライタジン · ブラウリベラ · ザメック
識別子と物理属性
| CAS No. | 66357-59-3 |
|---|---|
| 分子式 | C13H23ClN4O3S |
| 平均分子量 | 350.87 g/mol |
| 単同位体質量 | 350.1179395 g/mol |
| SMILES | CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl |
| InChIKey | GGWBHVILAJZWKJ-KJEVSKRMSA-N |
| PubChem CID | 3033332 |
| ChEMBL | CHEMBL2110372 |
| EC No. | 266-333-0 |
| 現地名 | ラニチジン塩酸塩 |
化学・物理的性質
| 極性表面積 | 112 |
|---|---|
| 水素結合供与体数 | 3 |
| 水素結合受容体数 | 7 |
| 回転可能結合数 | 9 |
| 重原子数 | 22 |
| 形式電荷 | 0 |
| 複雑度 | 347 |
| 融点 | 134°C (dec.) |
| 貯蔵条件 | 2-8°C |
| 溶解度 | H2O: 1.8 mg/mL水、2-ヒドロキシプロピル-β-シクロデキストリン、酢酸、メタノール、エタノール、ジメチルスルホキシドに可溶。クロロホルムに不溶。 |
| 外観・状態 | 個体 |
| pKa（酸解離定数） | 8.27 (pKa2) |
| 色 | タン |
| Merck | 14,8110 |
| BCS Class | 3/1 |
| 安定性 | 吸湿性 |
| 主な用途 | 医薬品（低分子化合物） |
| InChI | InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H31H/b13-9+ |
| InChIKey | GGWBHVILAJZWKJ-KJEVSKRMSA-N |
| SMILES | C(/NC)(\NCCSCC1OC(CN(C)C)=CC=1)=C/[N+]([O-])=O.[H]Cl |
| CAS データベース | 66357-59-3(CAS DataBase Reference) |
化学的特性
Off-White Crystalline Solid
安全性と法規制
| GHS 分類 | This chemical does not meet GHS hazard criteria for 3.9% (3 of 76) of reports.DangerH315 (85.5%): Causes skin irritation [Warning Skin corrosion/irritation]H317 (93.4%): May cause an allergic skin reaction [Warning Sensitization, Skin]H319 (86.8%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H334 (92.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]H335 (92.1%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 76 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 3 of 76 reports by companies.There are 12 notifications provided by 73 of 76 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| 規制情報 | Ranitidine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard |
| 有害性の概要 | Allergic contact dermatitis reported in pharmaceutical workers[Kanerva, p. 1170] Ranitidine is a drug to reduce acid secretion in the stomach. Many side effects have been reported after ingestion of therapeutic doses including, rarely, drug-induced hepatitis. [HSDB] |
| Hazard Classes and Categories | Skin Irrit. 2 (100%)Skin Sens. 1 (100%)Eye Irrit. 2 (100%)Resp. Sens. 1 (96.3%)STOT SE 3 (100%)Skin Irrit. 2 (85.5%)Skin Sens. 1 (93.4%)Eye Irrit. 2 (86.8%) |
用途
用途
生理・薬理作用研究用。
用途
ヒスタミンH2 受容体遮断剤 です。胃粘膜のヒスタミンH2受容体を遮断し、 胃酸分泌抑制作用を示します。H2 遮断作用は シメチジンの10倍以上です。ペプシン分泌 抑制作用を有します。
用途
ヒスタミンH2 受容体遮断剤 です。胃粘膜のヒスタミンH2 受容体を遮断し、 胃酸分泌抑制作用を示します。H2 遮断作用は シメチジンの10 倍以上です。ペプシン分泌 抑制作用を有します。
使用
An H-2 histamine receptor antagonistRanitidine hydrochloride is mainly used as an H2-receptor antagonist and helps in the treatment of gastrointestinal lesions because of excessive gastric acid secretion. It also serves as an antiulcer drug.